



March 1, 2023

To The Listing Department <b>National Stock Exchange of India Limited</b> Exchange Plaza, Bandra - Kurla Complex Bandra (East) <u>Mumbai - 400 051</u> <i>Stock Code : INDOCO-EQ</i>	To The Listing Department <b>Bombay Stock Exchange Limited</b> Floor 25, P. J. Towers, Dalal Street, <u>Mumbai - 400 001</u> <i>Stock Code : 532612</i>
---	---

Dear Sir/Madam,

**Subject: USFDA inspection at Indoco Remedies Limited's Plant II (Sterile Facility) and Plant III (OSD Facility) at Goa**

We would like to inform you that the United States Food and Drug Administration (USFDA) has conducted GMP inspection of Plant II (Sterile Facility) and Plant III (OSD Facility) at Goa. The inspection was conducted from 20<sup>th</sup> February, 2023 to 28<sup>th</sup> February, 2023.

The USFDA has issued Form 483 with four (4) observations, which will be addressed within stipulated time. We believe that this will not have an impact on the supplies and the existing revenues from these Facilities.

The Company is committed to maintain compliances across all our facilities with cGMP quality standards at all times.

This is for your information and record.

**Thanking you,  
Yours faithfully,  
For Indoco Remedies Limited**



**Ramanathan Hariharan  
Company Secretary & Head- Legal**